This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEC5E1KP_M.jpg
© Reuters.By Gina Lee
Investing.com – China’s Akeso Inc (HK:) made a splash as it debuted on the Hong Kong Stock Exchange, with its stock soaring up to HK$24.45 ($3.21).
This is a 49% increase from its HK$16.18 initial offering price. The stocks opened at HK$23.50 and were trading at HK$ 23.8 by 1:08 AM ET (6:08 AM GMT).
Based in Zhongshan, the company develops drugs to treat cancers. It saw its HK$2.6 billion ($335.45 million) IPO, Hong Kong biggest so far this year, massively oversubscribed last week as the city’s investors snapped up the 5.95 million shares on offer.
Akeso is also working on a marketing tie-up with pharmaceutical giant Sino Biopharmaceuticals in the aftermath of the IPO’s success. It also aims to apply for approval to sell its drug candidate for classical Hodgkin’s lymphoma patients by June.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
